Avijit Dey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avijit Dey has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Amit Agrawal
Department of Neurosurgery All India Institute of Medical Sciences Bhopal Madhya Pradesh India
1 shared publication - Amitava Paul
Visva-Bharati University
1 shared publication Benoy Ray
Department of Community Medicine, D.N.De Homoeopathic Medical College and Hospital, Govt. of West Bengal, Tangra, Kolkata, West Bengal, India
1 shared publication- Chanchal Bhattacharya
Department of Animal Husbandry Government of Delhi Zoravar Singh Marg Tis Hazari 110054 Delhi- India
1 shared publication Dibyendu Mandal
Department of Homoeopathic Pharmacy, D.N.De Homoeopathic Medical College and Hospital, Govt. of West Bengal, Tangra, Kolkata, West Bengal, India
1 shared publication- Ezequiel Garcia-Ballestas
Centro de Investigaciones Biomédicas (CIB) Universidad de Cartagena Cartagena de Indias
1 shared publication
Latest Publications
- 29 October 2021
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 111 (02) , 097-104
Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19 Pandemic: A Community-Based, Cluster-Randomized Trial
Introduction There is some evidence that homeopathic treatment has been used successfully in previous epidemics, and currently some countries are testing homeoprophylaxis for the coronavirus disease 2019 (COVID-19) pandemic. There is a strong tradition of homeopathic treatment in India: therefore, we decided to compare three different homeopathic medicines against placebo in prevention of COVID-19 infections. Methods In this double-blind, cluster-randomized, placebo-controlled, four parallel arms, community-based, clinical trial, a 20,000-person sample of the population residing in Ward Number 57 of the Tangra area, Kolkata, was randomized in a 1:1:1:1 ratio of clusters to receive one of three homeopathic medicines (Bryonia alba 30cH, Gelsemium sempervirens 30cH, Phosphorus 30cH) or identical-looking placebo, for 3 (children) or 6 (adults) days. All the participants, who were aged 5 to 75 years, received ascorbic acid (vitamin C) tablets of 500 mg, once per day for 6 days. In addition, instructions on healthy diet and general hygienic measures, including hand washing, social distancing and proper use of mask and gloves, were given to all the participants. Results No new confirmed COVID-19 cases were diagnosed in the target population during the follow-up timeframe of 1 month—December 20, 2020 to January 19, 2021—thus making the trial inconclusive. The Phosphorus group had the least exposure to COVID-19 compared with the other groups. In comparison with placebo, the occurrence of unconfirmed COVID-19 cases was significantly less in the Phosphorus group (week 1: odds ratio [OR], 0.1; 95% confidence interval [CI], 0.06 to 0.16; week 2: OR, 0.004; 95% CI, 0.0002 to 0.06; week 3: OR, 0.007; 95% CI, 0.0004 to 0.11; week 4: OR, 0.009; 95% CI, 0.0006 to 0.14), but not in the Bryonia or Gelsemium groups. Conclusion Overall, the trial was inconclusive. The possible effect exerted by Phosphorus necessitates further investigation. Trial registration: CTRI/2020/11/029265.
- 29 October 2021
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 111 (02) , 097-104
Homeopathic Medicines Used as Prophylaxis in Kolkata during the COVID-19 Pandemic: A Community-Based, Cluster-Randomized Trial
Introduction There is some evidence that homeopathic treatment has been used successfully in previous epidemics, and currently some countries are testing homeoprophylaxis for the coronavirus disease 2019 (COVID-19) pandemic. There is a strong tradition of homeopathic treatment in India: therefore, we decided to compare three different homeopathic medicines against placebo in prevention of COVID-19 infections. Methods In this double-blind, cluster-randomized, placebo-controlled, four parallel arms, community-based, clinical trial, a 20,000-person sample of the population residing in Ward Number 57 of the Tangra area, Kolkata, was randomized in a 1:1:1:1 ratio of clusters to receive one of three homeopathic medicines (Bryonia alba 30cH, Gelsemium sempervirens 30cH, Phosphorus 30cH) or identical-looking placebo, for 3 (children) or 6 (adults) days. All the participants, who were aged 5 to 75 years, received ascorbic acid (vitamin C) tablets of 500 mg, once per day for 6 days. In addition, instructions on healthy diet and general hygienic measures, including hand washing, social distancing and proper use of mask and gloves, were given to all the participants. Results No new confirmed COVID-19 cases were diagnosed in the target population during the follow-up timeframe of 1 month—December 20, 2020 to January 19, 2021—thus making the trial inconclusive. The Phosphorus group had the least exposure to COVID-19 compared with the other groups. In comparison with placebo, the occurrence of unconfirmed COVID-19 cases was significantly less in the Phosphorus group (week 1: odds ratio [OR], 0.1; 95% confidence interval [CI], 0.06 to 0.16; week 2: OR, 0.004; 95% CI, 0.0002 to 0.06; week 3: OR, 0.007; 95% CI, 0.0004 to 0.11; week 4: OR, 0.009; 95% CI, 0.0006 to 0.14), but not in the Bryonia or Gelsemium groups. Conclusion Overall, the trial was inconclusive. The possible effect exerted by Phosphorus necessitates further investigation. Trial registration: CTRI/2020/11/029265.
- 1 April 2020
- Published by Negah Scientific Publisher in Iranian Journal of Neurosurgery
- Vol. 6 (2) , 101-103
Prioritizing the Neurosurgical Patients’ Care: Limited Resources and Successful Management in COVID-19 Pandemic
COVID-19 has become an alarming pandemic for our earth. Worldwide, healthcare workers including neurosurgeons are facing challenges in prioritizing neurosurgical patients. Here we have tried to draw attention to the effective management of patients with limited resources. Prioritizing surgical cases in emergencies, overseeing triage framework for neurosurgeries, rebuilding of the inpatient service, should be of utmost priority. Neurosurgeons should point in the amendment as far as a good life for everybody, while still prioritizing equity in the distribution of services.
- 1 April 2020
- Published by Negah Scientific Publisher in Iranian Journal of Neurosurgery
- Vol. 6 (2) , 101-103
Prioritizing the Neurosurgical Patients’ Care: Limited Resources and Successful Management in COVID-19 Pandemic
COVID-19 has become an alarming pandemic for our earth. Worldwide, healthcare workers including neurosurgeons are facing challenges in prioritizing neurosurgical patients. Here we have tried to draw attention to the effective management of patients with limited resources. Prioritizing surgical cases in emergencies, overseeing triage framework for neurosurgeries, rebuilding of the inpatient service, should be of utmost priority. Neurosurgeons should point in the amendment as far as a good life for everybody, while still prioritizing equity in the distribution of services.